08
Sep
Boom in unproven cell therapies intensifies regulatory debate
Steve Gschmeissner/SPL Thomas Albini met his first patient blinded by a stem-cell ‘treatment’ last year. The elderly woman, who had macular degeneration, thought she was paying to participate in a clinical trial that would save her sight by injecting stem cells into both eyes. Instead, it left her legally blind.
